BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 21, 2007
View Archived Issues
Peramivir Stumbles In Phase II Influenza Study; BioCryst Falls
Shares of BioCryst Pharmaceuticals Inc. tumbled more than 30 percent following a Phase II miss with the influenza drug peramivir, despite assurances from company executives that inadequate needle-lengths were to blame. (BioWorld Today)
Read More
House Passes Long-Awaited Legislation On FDA Reform
Read More
NewCo News: ImmunoBiosciences Using ICV Platform To Improve Vaccines
Read More
Progenics Raises $57M Publicly; Cellerix Gets $40M In Series B
Read More
Other News To Note
Read More
ICAAC Roundup
Read More
Clinic Roundup
Read More